



DEPRESCRIBING: WHAT DO I NEED TO KNOW?

Ellen Fulp, PharmD, MSPC, BCGP Director of Pharmacy Education, AvaCare, Inc. November 21, 2019



OBJECTIVES

- Briefly review the concept of medication appropriateness.
- Define and discuss deprescribing.
- Identify potentially nonessential medication classes for seriously ill patients.
- Discuss effective communication tips for having difficult deprescribing conversations.





MEDICATION APPROPRIATENESS


- Important factors for determining medication appropriateness:
 - Remaining life expectancy of patient
 - Time until therapeutic benefit of medication
 - Goals of care
 - Treatment target







MEDICATION APPROPRIATENESS









DEPRESCRIBING


DEPRESCRIBING

- Planned and supervised
- Process of dose reduction or discontinuation of medications that are potentially harmful or are no longer necessary
- Should be considered as an essential part of "good prescribing"





DEPRESCRIBING: WHAT'S THE BIG DEAL?







POLYPHARMACY

- "The simultaneous use of multiple drugs to treat a single ailment or condition"
- Risk increases ≥ five medications
- It is estimated that over half of Medicare beneficiaries receive at least five medications
- Adverse drug events, increased hospitalization, physical and cognitive decline, drug-drug interactions, falls, prescribing cascades







Anticholinergic Activity

Beers Criteria

Screening Tool of Older Person's Prescriptions (STOPP)

FORTA (Fit For The Aged) Medication Appropriateness Index CMS Endorsed NHPCO Relatedness Flow Chart







NONESSENTIAL MEDICATIONS

10

NONESSENTIAL MEDICATIONS: DISCONTINUATION

- Indications for discontinuation:
- Diminished benefit:
 - Clinical improvement
 - Stabilization
 - Lack of clinical response
- Increased risk:
 - Medication-related adverse effects
 - Drug interactions
 - Unsafe utilization (e.g., high-risk medications for an age group)







NONESSENTIAL MEDICATIONS: DISCONTINUATION

- Step one: MEDICATION RECONCILIATION
- Recognizing an indication for discontinuing a medication:
 - Lack of clinical benefit, adverse effects, clinical improvement
- Prioritize medications to be targeted for discontinuation
- Document approval of discontinuation recommendation
- Discontinue the medication(s) appropriately, coordinating with the patient, caregivers, and other providers
- Monitor the patient for beneficial and harmful effects of discontinuation





ADVERSE DRUG WITHDRAWAL EVENTS

- Significant set of signs or symptoms caused by the removal of a drug
- Often abbreviated ADWE to distinguish from adverse drug events (ADE)
- Commonly associated with: β-blockers, centrally acting sympatholytics, sedative hypnotics, opiates, tricyclic antidepressants, antipsychotics, stimulants and corticosteroids





HOSPICE: MEDICATIONS TO RECONSIDER

Medication Classes		
Anticoagulants	Cholinesterase Inhibitors	
Statins	Oral Diabetes Medications	
Antiplatelets	Vitamins & Supplements	
Diuretics	Antihypertensives	
Bisphosphonates	Psychogenic Agents	





G30.9: ALZHEIMER'S DISEASE



- Multiple comorbidities
- Increase in hospitalizations or ER visits
- Recent diagnosis of pneumonia or sepsis
- Weight loss
- Speech, <10 words per day
- Dysphagia
- Urinary and fecal incontinence
- Difficulty sitting or walking without assistance
- Flat affect





ACETYLCHOLINESTERASE INHIBITORS

Inhibition

Reversibly and noncompetitively inhibits acetylcholinesterase (enzyme responsible for the breakdown of acetylcholine)

Increase

Increased concentrations of acetylcholine available for synaptic transmission in the CNS


Improvement

Modest improvements in cognitive deficits





ANTIHYPERTENSIVES







J44.9: COPD

- Severe dyspnea at rest
- Unresponsive to bronchodilators
- Fatigue
- Chronic cough
- Increased hospitalizations and/or ER visits
- Increased respiratory infections
- Respiratory failure

- Hypoxemia
- Hypercapnia
- Right heart failure
- Resting tachycardia
- Weigh loss of >10% body weight





METERED DOSE INHALERS

- Wash hands with warm soapy water.
- Remove cap and hold inhaler upright.
- Shake inhaler.
- Breathe out slowly through mouth.
- Hold inhaler upright at mouth.

- While breathing in, press down on inhaler once to release medication.
- Continue to breathe in slowly and deeply.
- Hold your breath for 10 seconds.
- Rinse mouth thoroughly and spit.





150.9: HEART FAILURE, UNSP.



- Symptomatic on optimal therapy
- Angina at rest
- Symptomatic with exertion and symptomatic at rest
- Symptomatic arrhythmia
- History of cardiac arrest
- Syncopal episodes
- Brain bleed
- LVEF < 20%





ANTIPLATELETS AND ANTICOAGULANTS

Antiplatelets

- Aspirin
- Cilostazol
- Clopidogrel
- Prasugrel
- Ticagrelor

Anticoagulants

- Apixaban
- Edoxaban
- Rivaroxaban
- Warfarin





G31.1: SENILE DEGENERATION OF THE BRAIN



- Unintentional, significant weight loss (>10%)
- Assistance with multiple ADLs
- Serum albumin < 2.5 g/dL
- Dysphagia with aspiration
- Increasing hospitalizations
- Multiple comorbidities





SULFONYLUREAS

Action

- Stimulation of insulin from the pancreatic beta cells
- Decreased glucagon production in the liver

Utilization

Release of insulin moves glucose from the blood into cells

Reduction

Reduction in blood glucose levels





ORAL BISPHOSPHONATES

Binds to hydroxyapatite sites in bone

Inhibits osteoclast mediated bone resorption

Reduced bone turnover, increased bone mass, indirect increase in bone mineral density





C34.90: MAL NEO OF UNSPECIFIED PART OF UNSPECIFIED BRONCHUS OR LUNG




- PPS < 70%
- Assistance with ≥ 2 ADLs
- Metastatic disease
- Continued decline despite interventions
- Patient refusing further interventions
- Significant comorbidities





HMG-COA REDUCTASE INHIBITORS (STATINS)









COMMUNICATION TIPS

COMMUNICATION TIPS

- Professional behavior
- Open-ended questions
- Direct, honest, clear, specific
- Acknowledge limitations
- Consistent messages
 - Team communication
- Identify key family members and surrogate decision makers
- Continually adjust expectations
 - Individualized care







COMMUNICATION TIPS: WORDS MATTER




- -Individualized
- -Max benefit
- -Patient goals
- -Decrease burden

- -Stop
- -Quit
- -Cheap
- -Non-covered






COMMUNICATION TIPS: ASK-TELL-ASK







COMMUNICATION TIPS: BUILD







COMMUNICATION TIPS: SPIKES

50	דב	\mathbf{I}	n
	こし	u	U

• Plan, setting, sit down, eye contact, posture, timing

<u>Perception</u>

• Ask for current understanding

Invitation

Ask permission; how much information is desired?

<u>K</u>nowledge

 Provide information; be clear and direct; pause for questions and processing

Emotion

Attend to emotion before moving on; respond with empathy

Summarize & Strategize

• Plan for next steps; be concrete; confirmation







QUESTIONS?





THANK YOU!

REFERENCES

- Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther. 2009;85(1):103-7.
- McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP. The burden of polypharmacy in patients near the end
 of life. J Pain Symptom Manage. 2016; 51(2), 178-183.
- ASHP. "How to use metered-dose inhalers." <u>www.safemedication.com</u>. 2018. Accessed November 2019.
- Baily, FA, Harman, SM. Palliative care: The last hours and days of life. In: UpToDate, Bruera, E (Section Ed), UpToDate, Waltham, MA.
- Rosenstein, DL., Park E. Challenging interactions with patients and families in palliative care. In: UpToDate. Block, SD (Section Ed), UpToDate, Walthan, MA.
- Bain KT, et al., Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008 Oct;56(10):1946-52.
- Last AR, et al., Pharmacologic treatment of hyperlipidemia. Am Fam Physician. 2011; 84(5): 551-558.
- Abernethy AP, et al., Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness. J Clin Oncol. 32:52, 2014 (suppl; abstr LBA9514).





REFERENCES

- ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.
- American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012 Apr;60(4):616-31.
- Hallenbeck, James L. "Palliative Care Perspectives." Oxford University Press. 2003.
- Medicare Program; FY2020 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Requirements. 42 CFR Part 418 [CMS-1716-F]. Federal Register. 84 FR 38484. August 6, 2019. Final Rules.
- Scott IA, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015 May. 175(5):827-834.
- Gibert P, et al. Optimizing medication use in elderly people in primary care: Impact of STOPP criteria on inappropriate prescriptions. *Archives of Gerontology and Geriatrics*. 2018. 75: 16-19.
- Moriarty F, Bennett K, Kenny RA, Fahey T, Cahir C. Comparing potentially inappropriate prescribing tools and their association with patient outcomes. J Am Geriatr Soc. 2019 Nov. Epub ahead of print.
- Rochon PA. Drug prescribing for older adults. In: UpToDate, Schmader KE (Section Ed), UpToDate, Waltham, MA.



